Upstream Bio [UPB] vs Capricor [CAPR] Detailed Stock Comparison

Upstream Bio Inc.

NASDAQ
Loading...

Capricor Therapeutics Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 18 vital metrics comparison: Upstream Bio Inc. wins in 9 metrics, Capricor Therapeutics Inc. wins in 5 metrics, with 1 ties. Upstream Bio Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Upstream Bio Inc. Capricor Therapeutics Inc. Better
P/E Ratio (TTM) -3.50 -15.61 Upstream Bio Inc.
Price-to-Book Ratio 1.48 6.62 Upstream Bio Inc.
Debt-to-Equity Ratio 0.37 4.75 Upstream Bio Inc.
PEG Ratio -0.04 -0.05 Upstream Bio Inc.
EV/EBITDA -1.04 -16.23 Upstream Bio Inc.
Profit Margin (TTM) 0.00% 0.00% Tie
Operating Margin (TTM) -6,911.23% 0.00% Capricor Therapeutics Inc.
Return on Equity -35.44% -46.56% Upstream Bio Inc.
Return on Assets (TTM) -23.99% -25.68% Upstream Bio Inc.
Free Cash Flow (TTM) $-133.44M $-81.54M Capricor Therapeutics Inc.
1-Year Return -9.43% 202.93% Capricor Therapeutics Inc.
Price-to-Sales Ratio (TTM) 177.33 N/A N/A
Enterprise Value $165.87M $1.72B Capricor Therapeutics Inc.
EV/Revenue Ratio 58.12 N/A N/A
Revenue per Share (TTM) $0 $0 Upstream Bio Inc.
Earnings per Share (Diluted) $-2.66 $-2.26 Capricor Therapeutics Inc.
Beta (Stock Volatility) N/A 0.48 N/A
Short % of Float 8.56% 19.17% Upstream Bio Inc.

Upstream Bio Inc. vs Capricor Therapeutics Inc. Stock Performance Analysis

Loading Price Chart...

UPB
CAPR

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Upstream Bio Inc.5.24%-7.63%-18.05%3.67%-71.71%-71.81%
Capricor Therapeutics Inc.1.10%-5.15%-17.49%6.97%-7.74%-2.37%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Upstream Bio Inc.-9.43%-62.00%-62.00%-62.00%-62.00%-62.00%
Capricor Therapeutics Inc.202.93%558.46%676.17%-7.24%-90.64%-97.72%

Performance & Financial Health Analysis: Upstream Bio Inc. vs Capricor Therapeutics Inc.

MetricUPBCAPR
Market Information
Market Cap i$506.11M$2.04B
Market Cap CategorySmall capMid cap
10 Day Avg. Volume i595,120987,380
90 Day Avg. Volume i763,8601,234,213
Last Close$7.63$27.64
52 Week Range$7.18 - $33.68$4.30 - $40.37
% from 52W High-77.35%-31.53%
All-Time High$33.69 (Jan 14, 2026)$3,500.00 (Oct 22, 2007)
% from All-Time High-77.35%-99.21%
Growth Metrics
Quarterly Revenue Growth0.09%N/A
Quarterly Earnings Growth0.09%-1.00%
Financial Health
Profit Margin (TTM) i0.00%0.00%
Operating Margin (TTM) i-69.11%0.00%
Return on Equity (TTM) i-0.35%-0.47%
Debt to Equity (MRQ) i0.374.75
Cash & Liquidity
Book Value per Share (MRQ)$6.26$5.33
Cash per Share (MRQ)$6.28$5.53
Operating Cash Flow (TTM) i$-133,275,000$-69,811,264
Levered Free Cash Flow (TTM) i$-88,750,624$-39,600,748
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Upstream Bio Inc. vs Capricor Therapeutics Inc.

MetricUPB (Apr 26, 2026)CAPR (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i-3.50-15.61
Forward P/E i-2.88-56.73
PEG Ratio i-0.04-0.05
Price to Sales (TTM) i177.33N/A
Price to Book (MRQ) i1.486.62
Market Capitalization
Market Capitalization i$506.11M$2.04B
Enterprise Value i$165.87M$1.72B
Enterprise Value Metrics
Enterprise to Revenue i58.12N/A
Enterprise to EBITDA i-1.04-16.23
Risk & Other Metrics
Beta iN/A0.48
Book Value per Share (MRQ) i$6.26$5.33

Financial Statements Comparison: Upstream Bio Inc. vs Capricor Therapeutics Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricUPB (2025)CAPR (2025)
Revenue/Sales i2.85M0
Cost of Goods Sold iN/AN/A
COGS % of Revenue i0.0%-
Gross Profit iN/AN/A
Gross Margin i0.0%-
Research & Development i136.81M84.45M
Operating Income (EBIT) i-160.36M-108.14M
Operating Margin i-5,618.8%-
EBITDA i-160.17M-106.21M
EBITDA Margin i-5,612.2%-
Pre-Tax Income i-143.44M-105.04M
Pre-Tax Income % of Revenue i-5,026.0%-
Income Tax iN/A1,600
Income Tax % of Revenue i0.0%-
Net Income (Profit) i-143.44M-105.04M
Profit Margin i-5,026.0%-

Balance Sheet & Liquidity Metrics

MetricUPB (2025)CAPR (2025)
Cash & Equivalents i101.58M287.85M
Total Current Assets i351.80M322.94M
Total Current Assets % of Revenue i12,326.5%-
Total Current Liabilities i13.45M35.84M
Total Current Liabilities % of Revenue i471.3%-
Long-Term Debt i549,00014.32M
Long-Term Debt % of Revenue i19.2%-
Total Shareholders Equity i339.77M305.79M
Retained Earnings i-334.22M-304.88M
Retained Earnings % of Revenue i-11,710.7%-
Property, Plant & Equipment i1.22M22.27M

Cash Flow Statement Comparison

MetricUPB (2025)CAPR (2025)
Operating Cash Flow i-134.26M-71.86M
Operating Cash Flow % of Revenue i-4,704.4%-
Capital Expenditures i-165,000-11.72M
Free Cash Flow i-133.44M-81.54M
FCF Margin i-4,675.5%-
Debt Repayment iN/AN/A
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricUPBCAPR
Shares Short i3.02M10.04M
Short Ratio i3.737.73
Short % of Float i8.56%19.17%
Shares Outstanding i54.24M57.37M
Float Shares i34.59M48.61M
% Held by Insiders i14.88%9.47%
% Held by Institutions i95.64%53.91%
% Held by Public i-10.52%36.62%

Dividend Analysis & Yield Comparison: Upstream Bio Inc. vs Capricor Therapeutics Inc.

MetricUPBCAPR
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A